Sign In



Remember Me

MedlinePlus®

A service of the National Library of Medicine.

Resource Library



Print This Page   Add To My Folder
Powered by:adam.com

This information is provided by an independent source. Merck & Co., Inc. is not responsible for this content. Please discuss any and all treatment options with your healthcare professional. The manufacturer of a product generally has the most complete information about that product.

Chronic myelogenous leukemia (CML)

Definition

Chronic myelogenous leukemia is cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer grows from cells that produce white blood cells.

See also:

Alternative Names

CML; Chronic granulocytic leukemia; Leukemia - chronic granulocytic (CML)

Causes

CML can occur in adults (usually middle-aged) and children. The disease affects 1 to 2 people per 100,000 and makes up 7 - 20% cases of leukemia. It is usually associated with a chromosome abnormality called the Philadelphia chromosome.

Exposure to ionizing radiation is one possible trigger for this chromosome abnormality. Such exposure could occur from a nuclear disaster or from treatment of a previous cancer such as thyroid cancer or Hodgkin's lymphoma. It takes many years to develop leukemia from this cause. However, most people treated for cancer with radiation do not go on to develop leukemia, and most patients with CML have not been exposed to radiation.

Symptoms

CML causes rapid growth of the blood-forming cells (myeloid precursors) in the bone marrow, blood, and body tissues.

Chronic myelogenous leukemia is grouped into several phases:

  • Chronic
  • Accelerated
  • Blast crisis

The chronic phase can last for months or years. The disease may have few or no symptoms during this time. Most people are diagnosed during this stage, when they are having blood drawn for other reasons.

The accelerated phase is a more dangerous phase, during which the leukemia cells grow more quickly. This phase may be associated with fever (without infection), bone pain, and a swollen spleen.

If untreated, CML progresses to the blast crisis phase. Bleeding and infection may occur due to bone marrow failure. Other possible symptoms include:

Exams and Tests

A physical examination often reveals a swollen spleen. A complete blood count (CBC) shows an increased number of white blood cells.

Other tests that may be done include:

This disease may also alter the results of the following tests:

Treatment

This version of the Encyclopedia has no treatment information. Please discuss any and all treatment options for your condition with your healthcare professional.

Support Groups

See:

Outlook (Prognosis)

Since the introduction of Gleevec, the outlook for patients with CML has improved dramatically. When the signs and symptoms of CML go away, you are said to be in remission. Many patients can remain in remission for many years while on this drug.

Transplantation should be considered in all patients whose disease comes back after initial treatment with imatinib (Gleevec). Long-term cure after transplantation ranges from 60 - 80%.

Possible Complications

Blast crisis can lead to complications of CML, including infection, bleeding, fatigue, unexplained fever, and kidney problems. Chemotherapy can have serious side effects, depending on the drugs used.

When to Contact a Medical Professional

Call your health care provider if you have symptoms of CML or have been diagnosed with CML and develop a fever higher than 100°F, chills, sore throat, or cough.

Prevention

Avoid exposure to radiation when possible.

References

Kantarjian H, O'Brien S. The chronic leukemias. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 195.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Chronic myelogenous leukemia. National Comprehensive Cancer Network; 2009. Version 2.2009.


Review Date: 2/12/2009
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com
 

 

Print This Page   Add To My Folder